Skip to content

JDS Pharma: what changed

BE 1012.963.476NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€30,345
2024 · €10,197+€20,148
Equity
€43,542
2024 · €13,197+€30,345
Cash
€59,517
2024 · €15,052+€44,465
Balance sheet total
€63,805
2024 · €26,092+€37,713

Largest movements

2024 to 2025
Assets
  • Cash +€44,465

    up €44,465 (+295%), from €15,052 to €59,517

    mainly Net result for the year (+€30,345) and Tax, wage and social debts (+€8,494)

  • Receivables within one year -€6,618

    down €6,618 (-60.7%), from €10,907 to €4,288

    of which Trade receivables: -€6,795

Equity and liabilities
  • Profit (loss) carried forward +€30,345

    up €30,345 (+298%), from €10,197 to €40,542

  • Tax, wage and social debts +€8,494

    up €8,494 (+87.1%), from €9,752 to €18,245

  • Other debts -€966

    down €966 (-48.8%), from €1,977 to €1,012

Income statement
  • Gross operating margin +€27,219

    up €27,219 (+205%), from €13,256 to €40,475

  • Taxes +€5,735

    up €5,735 (+216%), from €2,658 to €8,393

  • Other operating charges +€1,286

    up €1,286 (+341%), from €377 to €1,663

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €10,197
Gross operating margin +€27,219
Other operating charges -€1,286
Financial income +€0
Financial charges -€50
Taxes -€5,735
Result 2025 €30,345
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€44,465
Investment €0
Financing €0
Cash 2024 €15,052
Net result for the year +€30,345
Receivables within one year +€6,618
Deferred charges and accrued income +€133
Trade debts -€160
Tax, wage and social debts +€8,494
Other debts -€966
Cash 2025 €59,517
brings cash intakes cash out
Every line side by side 29 lines
Line Code 2024 2025 Change %
Total assets 20/58 €26,092 €63,805 +€37,713 +145%
Current assets 29/58 €26,092 €63,805 +€37,713 +145%
Amounts receivable within one year 40/41 €10,907 €4,288 -€6,618 -60.7%
Trade receivables 40 €9,878 €3,083 -€6,795 -68.8%
Other amounts receivable 41 €1,028 €1,205 +€177 +17.2%
Cash at bank and in hand 54/58 €15,052 €59,517 +€44,465 +295%
Deferred charges and accrued income 490/1 €133 - -€133
Total equity and liabilities 10/49 €26,092 €63,805 +€37,713 +145%
Equity 10/15 €13,197 €43,542 +€30,345 +230%
Contributions 10/11 €3,000 €3,000 = 0.0%
Profit (loss) carried forward 14 €10,197 €40,542 +€30,345 +298%
Amounts payable 17/49 €12,895 €20,263 +€7,368 +57.1%
Amounts payable within one year 42/48 €12,895 €20,263 +€7,368 +57.1%
Trade debts 44 €1,166 €1,005 -€160 -13.8%
Suppliers 440/4 €1,166 €1,005 -€160 -13.8%
Taxes, remuneration and social security 45 €9,752 €18,245 +€8,494 +87.1%
Taxes 450/3 €9,752 €18,245 +€8,494 +87.1%
Other amounts payable 47/48 €1,977 €1,012 -€966 -48.8%
Other operating charges 640/8 €377 €1,663 +€1,286 +341%
Gross operating margin 9900 €13,256 €40,475 +€27,219 +205%
Operating profit (loss) 9901 €12,878 €38,812 +€25,934 +201%
Financial income 75/76B - €0 +€0
Recurring financial income 75 - €0 +€0
Financial charges 65/66B €24 €74 +€50 +215%
Recurring financial charges 65 €24 €74 +€50 +215%
Profit (loss) for the period before taxes 9903 €12,855 €38,738 +€25,883 +201%
Income taxes 67/77 €2,658 €8,393 +€5,735 +216%
Profit (loss) for the period 9904 €10,197 €30,345 +€20,148 +198%
Profit (loss) for the period to be appropriated 9905 €10,197 €30,345 +€20,148 +198%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€94,168 to €123,126

Midpoint €106,234 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €43,542
Capitalised earnings €144,793 to €202,710
Indication €94,168 to €123,126

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€43,542
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€43,542

Capitalised earnings

net result for the year (9904)
2025
€30,345
2024
€10,197
Average result
€20,271
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€144,793 / €168,925 / €202,710

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 17 November 2026 via checked.be.